Manajemen Psoriasis Pustulosa
DOI:
https://doi.org/10.55175/cdk.v50i3.658Kata Kunci:
Psoriasis, Psoriasis pustulosaAbstrak
Psoriasis merupakan penyakit radang kulit kronis dengan dasar genetik yang kuat. Berdasarkan tipenya, psoriasis dibagi menjadi psoriasis plak (psoriasis vulgaris), psoriasis gutata, psoriasis pustulosa generalisata/lokalisata, psoriasis inversa, dan eritroderma psoriatika. Manajemen psoriasis pustulosa mempertimbangkan tingkat keparahan penyakit. Acitretin, cyclosporine, methotrexate, dan infliximab merupakan terapi lini pertama untuk psoriasis pustular generalisata. Adalimumab, etanercept, dan psoralen plus ultraviolet A (PUVA) adalah modalitas lini kedua. Berbagai modalitas terapi lain yang sedang dikembangkan adalah agen biologis dan terapi berdasar sel punca. Manajemen psoriasis pustulosa dapat menggunakan berbagai modalitas dengan memperhatikan kondisi pasien dan keterjangkauan terapi
Psoriasis is a chronic skin inflammation with a strong genetic basis. Based on its type, psoriasis is divided into plaque psoriasis (psoriasis vulgaris), guttate psoriasis, generalized/localized pustular psoriasis, inverse psoriasis, and psoriatic erythroderma. The management of pustular psoriasis depends on the disease severity. Acitretin, cyclosporine, methotrexate, and infliximab are first-line therapies for generalized pustular psoriasis. Adalimumab, etanercept, and psoralen plus ultraviolet A (PUVA) are second-line modalities. Other therapeutic modalities being developed are biologic agents and stem cell-based therapies. Management of pustular psoriasis can use various modalities, depending on the patient’s condition and its affordability
Unduhan
Referensi
Gudjonsson JE, Elder JT. Psoriasis. In: Kang S, Amagai M, Bruckner A, Enk A, Margolis D, McMichael A, editor. Fitzpatrick’s dermatology. 9th ed. New York: McGraw-Hill; 2018 .p. 457–97
Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol. 2018;179: 614-8
Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: A review and update on treatment. JEADV. 2018;1:1-7
Lwin SM, Snowden JA, Griffiths CEM. The promise and challenges of cell therapy for psoriasis. Br J Dermatol. 2021;1:1-12
Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27:1067-77.
Bissonnette R, Suarez-Farinas M, Li X. Based on molecular profiling of gene expression, palmoplantar pustulosis and palmoplantar pustular psoriasis are highly related diseases that appear to be distinct from psoriasis vulgaris. PLoS One 2016;11(5):e0155215.
Kim KH, Kim HL, Suh HY. A case of acrodermatitis continua accompanying with osteolysis and atrophy of the distal phalanx that evoluted into generalized pustular psoriasis. Ann Dermatol. 2016;28(6):794-5.
Gooderham MJ, Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;1:1-14
Yuliastuti D. Psoriasis. Cermin Dunia Kedokteran. 2015;42(12):901-6.
Benjegerdes KE, Hyde K, Kivelevitch D. Pustular psoriasis: Pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131–44.
Furue K, Yamamura K, Tsuji G, Mitoma C, Uchi H, Nakahara T, et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98:5–13
Magis NL, Blummel JJ, Kerkhof PC, Gerritsen,RM. The treatment of psoriasis with etretinate and acitretin: A follow up of actual use. Eur J Dermatol. 2000;10:517-21.
Mengesha YM, Bennett ML. Pustular skin disorders: Diagnosis and treatment. Am J Clin Dermatol. 2002;3:389-400
Robinson A, Van Voorhees AS, Hsu S. Treatment of pustular psoriasis: From the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–88.
Napolitano M, Megna M, Balato A. Systemic treatment of pediatric psoriasis: A review. Dermatol Ther (Heidelb). 2016;(2):125–42.
Pathirana D, Ormerod AD, Saiag P. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(suppl 2):1-70.
Shirolikar M, Pande S, Borkar M, Soni S. Manageing a side effect: Cyclosporine-induced nephrotoxicity. Indian J Drug in Dermatol. 2018;4(1):39-44
Fujita H, Terui T, Hayama K. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol. 2018;45 (11):1235–70.
Hansel K, Bianchi L, Lanza F. Adalimumab dose tapering in psoriasis: Predictive factors for maintenance of complete clearance. Acta Derm Venereol. 2017;97:346–50.
Li Z, Xiao S, Ren J, Zhang Y, Tu C, Ji F. Hepatotoxicity due to etanercept abated after dose reduction in a patient with pustular psoriasis and without compromised efficacy. Rev Esp Enferm Dig. 2014;106:492–3.
Emer J, Frankel A, Zeichner J. A practical approach to monitoring patients on biological agents for the treatment of psoriasis.J Clin Aesthetic Dermatol. 2010;3(8):20-6.
Vissers WH, Berends M, Muys L. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol. 2004;13(2):106.
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643.
Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/Interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016;152:825–8.
Imafuku S, Honma M, Okubo Y. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011–7.
Hou R, Li J, Niu X, Liu R, Chang W, Zhao X, et al. Stem cells in psoriasis. J Dermatoll Sci. 2017;86:181–6
Saczonek AO, Włodarczyk MK, Kruszewska A, Placek W, Maksymowicz W, Wojtkiewicz J. Stem cells as potential candidates for psoriasis cell-replacement therapy. Internat J Mol Sci. 2017;18:1-16.
Mori J, Kakihana K, Ohashi K. Sustained remission of psoriasis vulgaris after allogeneic bone marrow transplantation. Br J Haematol. 2012;159:121
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2023 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
